Summit Financial’s Novavax NVAX Stock Holding History

Summit Financial’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,275	Closed	-$220K	–	258
2022 Q2	$220K	Buy	4,275 +15	+0.4%	+$777	0.02%	221
2022 Q1	$314K	Buy	+4,260	New	+$380K	0.02%	215

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Summit Financial's NVAX Position: Q3 2022 in Review

Summit Financial sold out of Novavax (NVAX) in Q3 2022, closing a stake of 4,275 shares — an estimated $220K sold.

Summit Financial first reported a position in NVAX in Q1 2022 and held it in 2 quarters. The position peaked at $314K in Q1 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Summit Financial reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Summit Financial sold 4,275 Novavax shares in Q3 2022, an estimated $220K.
Summit Financial first reported a position in Novavax in Q1 2022 and held it in 2 quarters.
Summit Financial's Novavax position peaked at $314K in Q1 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Summit Financial's 13F filing for Q3 2022, filed 15 Nov 2022.